Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 43

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 43
---
 these countries.

Our success depends in significant part on our
ability to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to our drug candidates and
technology and to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights of
others. If we are unable to obtain and maintain sufficient intellectual property protection for our drug candidates or other drug candidates
that we may identify, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors and
other third parties could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize
our drug candidates and other drug candidates that we may pursue may be impaired.

<div align='center'>20</div>

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on our business.

Our success depends, in part, on our ability to
protect our proprietary rights to the technologies used in our product candidates. We depend heavily upon confidentiality agreements with
our officers, employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures may not afford
us complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure of confidential
information. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively against
us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts to recover
or restrict use of our intellectual property. In addition, others may independently develop technology similar to ours, otherwise avoiding
the confidentiality agreements, or produce patents that would materially and adversely affect our business, prospects, financial condition
and results of operations, in which event you could lose all of your investment.

We may enter into licensing and collaboration agreements with third parties. If we fail to comply with our obligations in the agreements under which we license intellectual property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to our business relationships with our licensors or licensees, our competitive position, business, financial condition, results of operations and prospects could be harmed.

It may be necessary for us to use the patented
or proprietary technology of third parties to commercialize our products (if approved), in which case we would be required to obtain a
license from these third parties.